Metabolic Syndrome (eBook, ePUB)

Underlying Mechanisms and Drug Therapies
Redaktion: Wang, Minghan

• Format: ePub

Produktbeschreibung

METABOLIC SYNDROME A comprehensive look at the fight against the metabolic syndrome epidemic Increasing risk of cardiovascular disease and diabetes, the metabolic syndrome is a world health problem that demands attention from all levels of the health care industry. Metabolic Syndrome: Underlying Mechanisms and Drug therapies extensively covers the metabolic syndrome with an emphasis on drug discovery efforts, providing a context of molecular mechanisms and drug pharmacology for pharmaceutical scientists. The book starts by examining the physiology of metabolic tissues under normal and disease states, followed by discussions of metabolic diseases and clinical complications. The development of drug therapies based on emerging science is then covered extensively. In addition, there is an in-depth look into the metabolic pathways and dysfunctions in metabolic disease, especially type 2 diabetes and lipid disorders. Finally, a chapter is devoted to past successes and failures in metabolic drug discovery as well as an outlook on future development and challenges. Divided into four parts, the book: * Addresses important metabolic syndrome basics at the psychological level and metabolic abnormalities at the tissue and pathway levels * Covers the identification of pathways and molecular targets for the development of anti-diabetic therapies * Details pharmaceutical industry approach to solving metabolic and obesity related problems * Describes drug therapies and their limitations and complications, offering a "lessons learned" from existing treatments With a clear organization and extensive collection of references, the book is a user-friendly and unique tool for scientists in a variety of scientific disciplines in the pharmaceutical and biotechnology industries.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: John Wiley & Sons
• Seitenzahl: 508
• Erscheinungstermin: 18. April 2011
• Englisch
• ISBN-13: 9780470922712
• Artikelnr.: 37300548

Autorenporträt

MINGHAN "MING" WANG, PHD is Director and head of a metabolism group in Metabolic Disorders Research at Amgen. He has authored over forty publications and is a regular speaker at drug discovery conferences.

Inhaltsangabe

Introduction (Minghan Wang). Contributors. Part I. The physiology of
metabolic tissues under normal and disease states. Chapter 1: Gut as an
endocrine organ: the role of nutrient-sensing in energy metabolism (Minghan
Wang). Chapter 2: Central glucose sensing and control of food intake and
energy homeostasis (Lourdes Mounien and Bernard Thorens). Chapter 3:
Abnormalities in insulin secretion in type 2 diabetes mellitus (Taly Meas
and Pierre-Jean Guillausseau). Chapter 4: Adipokine production by adipose
tissue: A novel target for treating metabolic syndrome and its sequelae
(Vanessa DeClercq, Danielle Stringer, Ryan Hunt, Carla G. Taylor, and Peter
Zahradka). Chapter 5: Hepatic metabolic dysfunctions in type 2 diabetes:
Insulin resistance and impaired glucose production and lipid synthesis
(Ruojing Yang). Chapter 6: Energy metabolism in skeletal muscle and its
link to insulin resistance (Minghan Wang). Part II. Metabolic diseases and
current therapies. Chapter 7: Mechanisms and complications of metabolic
syndrome (Minghan Wang). Chapter 8: Emerging therapeutic approaches for
dyslipidemia associated with high LDL and low HDL (Margrit Schwarz and Jae
B. Kim). Chapter 9: Mechanism of action of niacin: implications for
atherosclerosis and drug discovery (Devan Marar, Shobha H. Ganji, Vaijinath
S. Kamanna, and Moti L. Kashyap). Chapter 10: Current anti-diabetic
therapies and mechanisms (Minghan Wang). Part III. Drug targets for
anti-diabetic therapies. Chapter 11: GLP-1 biology, signaling mechanisms,
physiology, and clinical studies (Remy Burcelin, Cendrine Cabou1,
Christophe Magnan, and Pierre Gourdy). Chapter 12: Dipeptidyl peptidase IV
inhibitors for treatment of diabetes (McIntosh, CHS, Kim, S-J., Pederson,
RA, Heiser, U, and Demuth, H-U). Chapter 13: Sodium glucose co-transporter
2 inhibitors (Margaret Ryan and Serge A. Jabbour). Chapter 14: Fibroblast
growth factor 21 as a novel metabolic regulator (Radmila Micanovic, James
D. Dunbar, and Alexei Kharitonenkov). Chapter 15: Sirtuins as potential
drug targets for metabolic diseases (Qiang Tong). Chapter 16:
11?-hydroxysteroid dehydrogenase type 1 as a therapeutic target for type 2
diabetes (Clarence Hale and David J. St. Jean, Jr.). Chapter 17: Monoclonal
antibodies for the treatment of type 2 diabetes: A case study with glucagon
receptor blockade (Hai Yan, Wei Gu, and Murielle Veniant-Ellison). Part IV.
Lessons learned and future outlook. Chapter 18: Drug development for
metabolic diseases: past, present and future (Minghan Wang). Index.